Vaylen Review
Best for: GLP-1-focused care with oral and injectable options across all 50 states
Vaylen is a pure GLP-1 specialist offering compounded semaglutide ($179/mo), compounded tirzepatide ($239/mo), compounded oral GLP-1 ($259/mo), and brand-name Ozempic, Zepbound, and Wegovy. LegitScript certified. Licensed clinicians in all 50 states.
High confidence · Last verified 2026-04-10 via manual · How we verify provider data
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
The Bottom Line
Vaylen is a solid telehealth option with balanced features and pricing.
Score Breakdown
Pricing
| Dose | Form | Price/mo |
|---|---|---|
| Compounded Semaglutide | compounded | $179 |
| Compounded Tirzepatide | compounded | $239 |
| Compounded Oral GLP-1 | compounded | $259 |
| Ozempic | brand | $997 |
| Zepbound | brand | $1086 |
| Wegovy | brand | $1350 |
✓ Pros
- •Pure GLP-1 specialist — not a multi-category telehealth platform
- •All 50 states coverage with licensed clinicians
- •Both compounded and brand-name options (Ozempic, Wegovy, Zepbound)
- •Oral GLP-1 option (compounded dissolvable tablets) for needle-averse patients
- •LegitScript certified
- •Transparent pricing — no hidden costs, no insurance required
- •Continuous coaching and lab support included
✗ Cons
- •Compounded semaglutide at $179/mo is mid-range (not the cheapest)
- •Brand-name options at near-retail pricing ($997–$1,350/mo)
Ready to start with Vaylen?
Starting at $179/month. See current pricing and start your free consultation.
Sources & methodology
Our Vaylen review applies the same 6-dimension scoring framework we use for every provider. Pricing, FDA approval status, compounding rules, and clinical-trial efficacy claims are sourced from the primary regulatory and peer-reviewed literature below.
Sources & methodology — as of April 2026
- 1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)— WeightLossRankings.org.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 9.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 10.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 11.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 12.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
Alternatives to Vaylen
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Frequently Asked Questions
Ready to start with Vaylen?
Starting at $179/month. See current pricing and start your free consultation.